

Supplementary Appendix 2: Relative ratios, seroconversion and proportion attaining the median convalescent serum level after BNT162b2 or mRNA-1273 vaccination in patients with serology at both 6-7 weeks and 12 weeks

Antibody	Weeks after second dose	Relative ratio, median (IQR)			No. (%) of patients with seroconversion			No. (%) of patients who reached convalescent level		
		BNT162b2	mRNA-1273	p-value	BNT162b2	mRNA-1273	p-value	BNT162b2	mRNA-1273	p-value
Anti-spike	6-7	1.58 (1.39-1.68)	1.73 (1.69-1.79)	<0.001	60 (87) n=63	61 (97) n=63	1.00	48 (76) n=63	60 (95) n=63	<0.001
	12	1.35 (0.86-1.52)	1.97 (1.75-2.05)	<0.001	61 (97) n=63	60 (95) n=63		28 (44) n=63	60 (95) n=63	
Anti-RBD	6-7	1.33 (0.71-1.64)	1.44 (1.29-1.52)	0.39	58 (92) n=63	60 (95) n=63	0.031	33 (52) n=63	50 (79) n=63	<0.001
	12	0.75 (0.28-1.34)	1.30 (1.04-1.46)	<0.001	53 (84) n=63	59 (94) n=63		20 (32) n=63	39 (62) n=63	
Anti-NP	6-7	0.055 (0.030-0.11)	0.060 (0.043-0.13)	0.24	11 (18) n=63	6 (10) n=63	0.38	3 (5) n=63	6 (10) n=63	0.69
	12	0.040 (0.020-0.090)	0.057 (0.035-0.11)	0.03	10 (16%) n=63	4 (6%) n=63		5 (8) n=63	2 (3) n=63	

Note: IQR=interquartile range, NP=nucleocapsid protein, RBD=receptor binding domain.

Note: Mann-Whitney test was used to compare antibody relative ratios at 6-7 weeks and 12 weeks while McNemar's test was used for comparison of proportions with seroconversion and reaching convalescent levels at 6-7 weeks and 12 weeks.